Thomas Julia D J, Monson John P
Department of Endocrinology, St Bartholomew's Hospital, Queen Mary University of London, UK.
Eur J Endocrinol. 2009 Nov;161 Suppl 1:S97-S106. doi: 10.1530/EJE-09-0258. Epub 2009 Aug 14.
It is now accepted that adults with severe GH deficiency (GHD) demonstrate impaired physical and psychological well-being and may benefit from replacement with recombinant human GH. Post-marketing surveillance surveys, such as the Pfizer International Metabolic Database (KIMS), were initially set-up to provide safety data on long-term treatment but have the added benefit of providing ongoing observational data on the effect of GH replacement on body composition, lipid and glucose status, hypertension, bone density and quality of life. These data demonstrate that although GHD has clinical impact at all ages, the individual consequences of this condition may take on greater significance at different stages in life. At all ages, accurate, safe diagnosis and appropriate GH dosing are necessary to provide the individual with the best possible outcome.
目前公认的是，患有严重生长激素缺乏症（GHD）的成年人身心健康受损，使用重组人生长激素进行替代治疗可能会有益处。上市后监测调查，如辉瑞国际代谢数据库（KIMS），最初是为了提供长期治疗的安全性数据而设立的，但还有额外的好处，即能提供关于生长激素替代对身体成分、脂质和葡萄糖状况、高血压、骨密度及生活质量影响的持续观察数据。这些数据表明，尽管生长激素缺乏症在所有年龄段都有临床影响，但这种病症的个体后果在人生的不同阶段可能具有更大的意义。在所有年龄段，准确、安全的诊断和适当的生长激素剂量对于为个体提供最佳可能结果都是必要的。
